- Full phase 3 data for Apellis Pharmaceuticals' (NASDAQ:APLS) paroxysmal nocturnal hemoglobinuria (PNH) drug candidate pegcetacoplan indicates it is superior to Alexion Pharmaceuticals' (NASDAQ:ALXN) Soliris (eculizumab).
- The data was published in The New England Journal of Medicine.
- Full results from the